Alexander Chou, MD Specialties: Pediatric Hematology-Oncology
Please contact the doctor's office to verify that your insurance is accepted.
- Aetna - NYP
- Aetna - Weill Cornell
- Empire Blue Cross/Blue Shield
- Empire Blue Cross/Blue Shield Healthplus
- Health Insurance Plan of NY (HIP)
- Oxford Health Plans
- United Healthcare
About Alexander Chou, MD
Dr. Alexander Chou is an assistant professor of pediatrics at Weill Cornell Medicine and an assistant attending pediatrician at NewYork-Presbyterian/Weill Cornell Medical Center. He specializes in the care of children with pediatric sarcomas including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma, desmoplastic small round cell tumor, alveolar soft part sarcoma, rhabdoid tumors, epithelioid sarcomas, infantile fibrosarcomas, and other rare sarcomas of childhood, and also cares for children with other common solid tumors such as neuroblastoma, Wilm's tumor, hepatoblastoma, germ cell tumors, and other rarer tumors of childhood.
Dr. Chou received his medical degree (M.D.) at Weill Cornell Medical College, Cornell University. After completing his residency in Pediatrics at NewYork-Presbyterian/Weill Cornell Medical Center, he continued his training and completed a pediatric hematology/oncology fellowship at the joint program at Memorial Sloan Kettering Cancer Center and NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Chou joined the faculty at Memorial Sloan Kettering Cancer Center (MSKCC) where he served for a decade as a member of the pediatric sarcoma service and in various education leadership roles. He then served as clinical director of the pediatric sarcoma service at the Children's Hospital at Montefiore, where he helped establish the Bronx's first pediatric cancer predisposition clinic. In 2021, he was recruited to rejoin the faculty at Weill Cornell Medicine to provide direct care for children with solid tumors and serve as the Director for Clinical Operations for Pediatric Oncology.
Dr. Chou's research and clinical interests lie in exploring new treatment options for pediatric sarcomas and pediatric solid tumors. In the laboratory, he has sought to characterize the molecular pathways that led to tumor growth and progression. Additionally, he helped develop novel drugs and treatment delivery mechanisms for relapsed pediatric sarcomas. He is active in regional, national and international collaborative organizations including the Children's Oncology Group, the American Society of Pediatric Hematology Oncology, and the Connective Tissue Oncology Society.
Malignant Germ Cell Tumor
Pediatric Solid Tumors